Delavitt Castor

Otis Brawley, a renowned oncology professor at Johns Hopkins, and Delavitt Castor, an infectious disease expert at Columbia University, discuss the pressing challenges in U.S. cancer research. They tackle the consequences of recent funding cuts, particularly from the Trump administration, and the implications for clinical trials. The conversation reveals alarming disparities in cancer treatment and the urgent need for innovative solutions in public health to bridge these gaps. They also reflect on the intertwined relationship between politics and funding in advancing cancer research.